{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68"}]}],"title":"At least one TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"At least one SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, physical exams, and vital signs","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set is all participants who were enrolled and received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days after last dose of study drug (Up to approximately 3 years and 2.5 months)","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}